Illumina, Inc. (ILMN)
- Previous Close
117.43 - Open
118.58 - Bid 120.19 x 200
- Ask 120.36 x 200
- Day's Range
117.48 - 120.90 - 52 Week Range
89.00 - 228.13 - Volume
1,142,865 - Avg. Volume
1,682,575 - Market Cap (intraday)
19.15B - Beta (5Y Monthly) 1.19
- PE Ratio (TTM)
-- - EPS (TTM)
-7.34 - Earnings Date May 2, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
154.62
Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services; and Galleri, a multi-cancer early detection test. In addition, the company is developing solutions to help accelerate cancer diagnoses, blood-based detection for minimal residual disease, and other post-diagnostic applications. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. It markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. was incorporated in 1998 and is based in San Diego, California.
www.illumina.com10,590
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: ILMN
Performance Overview: ILMN
Trailing total returns as of 4/22/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ILMN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ILMN
Valuation Measures
Market Cap
19.16B
Enterprise Value
20.36B
Trailing P/E
--
Forward P/E
123.46
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
4.22
Price/Book (mrq)
3.33
Enterprise Value/Revenue
4.52
Enterprise Value/EBITDA
-33.49
Financial Highlights
Profitability and Income Statement
Profit Margin
-25.78%
Return on Assets (ttm)
-0.52%
Return on Equity (ttm)
-18.81%
Revenue (ttm)
4.5B
Net Income Avi to Common (ttm)
-1.16B
Diluted EPS (ttm)
-7.34
Balance Sheet and Cash Flow
Total Cash (mrq)
1.05B
Total Debt/Equity (mrq)
39.37%
Levered Free Cash Flow (ttm)
513.12M
Research Analysis: ILMN
Company Insights: ILMN
Fair Value
Dividend Score
Hiring Score
Insider Sentiment Score
Research Reports: ILMN
Analyst Report: Illumina Inc
Illumina Inc., based in San Diego, provides sequencing and array-based solutions for genetic analysis. The company's products and services are sold to genomic research centers, academic institutions, government and commercial laboratories, and hospitals, as well as to pharmaceutical, biotech, agrigenomics, and consumer genomics businesses. The company's portfolio of products and services is designed to accelerate and simplify genetic analysis. Illumina also invests in startup companies that are pursuing promising genomic-related opportunities. It has roughly 10,590 full-time employees, including 9,250 employees at Core Illumina and 1,340 employees at GRAIL. ILMN shares are included in the S&P 500 index.
RatingPrice TargetMarket Digest: ILMN, DIS, MCK, YUM, CAVA
The daily charts for the major indices all have a 'rolling-over' look, with the Nasdaq and Nasdaq 100 (QQQ) appearing to be ahead of the S&P 500 (SPX) for a break lower. As well, the news from the Middle East seems to be getting worse by the day -- but, so far, the U.S stock market and economy seem to be turning a blind eye to the potential implications. Crude oil prices, both WTI and Brent, aren't exploding, but have seen pretty good rallies. WTI hit $87.60/barrel at the end of last week from the low $70s just two months ago, while Brent almost reached $92 last week from $77 in early February.
Analyst Report: Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina’s high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2023 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
RatingPrice TargetAnalyst Report: Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina’s high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2023 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
RatingPrice Target